We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Researchers Demonstrate the Effectiveness of MRgFUS to Control Cancer Pain

By HospiMedica International staff writers
Posted on 27 Dec 2016
Researchers in Italy have shown that MR-guided high-intensity Focused Ultrasound (MRgFUS) is safe and effective in managing pain in cancer patients, and can reduce the dependence of these patients on opioid pain control medications.

The results were presented at the annual Radiological Society of North America (RSNA2016) meeting. More...
Clinicians often prescribe opioid medicines for pain relief however patients can become dependent on these medications, and MRgFUS is now being used as a non-invasive and innovative pain treatment method.

The researchers from the Sapienza University in Rome (Rome, Italy) used real-time ultrasound or Magnetic Resonance Imaging (MRI) monitoring to guide a transducer and focus ultrasound energy to the targeted area and destroy the target tissue.

The researchers achieved promising results for the management of pancreatic cancer patients. MRgFUS has also been found to be effective at reducing pain in patients with bone metastases and recurrent cervical carcinoma, especially when combined with chemotherapy, and radiation therapy.

Lead author of the study, Susan Dababou, medical student at Sapienza, said, "This population of patients often has a poor prognosis and low life expectancy. The cancer-specific therapy is often very debilitating and pain can be a worsening factor of the general condition of these patients. The patients with pancreatic cancer treated with focalized ultrasound energy by our group were followed for six months and the pain relief lasted for the whole period. There is evidence of at least nine months of pain relief in bone metastases treated with MRgFUS. In comparison with pharmacological treatment, MRgFUS acts on different fronts, ensuring an adequate pain relief, boosting the effect of chemotherapy and radiotherapy, and easing recovery. The compliance of the patients is favored by the noninvasiveness and non-toxicity of the procedure, and unlike pharmacologic therapy it is a single session treatment with mild or no complications."

Related Links:
Sapienza University in Rome


Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Enteral Feeding Pump
SENTINELplus
Morcellator
TCM 3000 BL
Gynecological Examination Chair
arco-matic
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.